RecruitingNot Applicable

Autoimmune Blistering Diseases Study

United States150 participantsStarted 2016-04

Plain-language summary

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons

What they're measuring

Pemphigus Disease Area Index (PDAI)

Timeframe: one year

Bullous Pemphigoid Disease Area Index (BPDAI)

Timeframe: one year

Trial details

NCT IDNCT02753777

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-01-02

Contact for this trial

Victoria P Werth, MD

215-615-2940 werth@pennmedicine.upenn.edu

View on ClinicalTrials.gov More Pemphigus Vulgaris trials